Polar Marine Bacteria: From Physiology to Biotechnological Applications

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Biotechnology Related to Drug Discovery or Production".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 1438

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemical Sciences, Federico II University of Naples, Complesso Universitario Monte S.- Angelo, Via Cintia, Naples, 80126, Italy
Interests: microbial physiology; microbial biotechnology; fermentation chemistry; drug discovery; prokaryotic molecular biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Polar marine bacteria face challenging conditions and to survive in such extreme conditions, they have developed specific mechanisms. The study of these mechanisms is stimulating from both a basic research and biotechnological perspective. The environmental selective pressure has driven the evolution of metabolic pathways responsible for synthesizing numerous enzymes, many of which are unique and possess intriguing biological properties. Furthermore, these bacteria have shown remarkable potential as sources of diverse extracellular metabolites with various biological activities, such as antibiotics, antitumor agents, surfactants, antibiofilm agents, and more. Despite the established interest in these bacteria, their full potential remains largely unexplored.

For this Special Issue, we invite researchers to submit reviews and original research articles that demonstrate new physiological and applicative studies on polar marine bacteria. We particularly welcome articles focusing on the discovery of bioactive molecules and cold-adapted enzymes, as well as the innovative use of these bacteria in biotechnological applications.

Prof. Dr. Ermenegilda Parrilli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive molecules
  • psychrophilic enzymes
  • marine bacteria
  • metabolomics
  • macromolecules
  • marine natural products
  • cold adaptation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2333 KiB  
Article
Cold-Azurin, a New Antibiofilm Protein Produced by the Antarctic Marine Bacterium Pseudomonas sp. TAE6080
by Caterina D’Angelo, Marika Trecca, Andrea Carpentieri, Marco Artini, Laura Selan, Maria Luisa Tutino, Rosanna Papa and Ermenegilda Parrilli
Mar. Drugs 2024, 22(2), 61; https://doi.org/10.3390/md22020061 - 25 Jan 2024
Viewed by 1278
Abstract
Biofilm is accountable for nosocomial infections and chronic illness, making it a serious economic and public health problem. Staphylococcus epidermidis, thanks to its ability to form biofilm and colonize biomaterials, represents the most frequent causative agent involved in biofilm-associated infections of medical [...] Read more.
Biofilm is accountable for nosocomial infections and chronic illness, making it a serious economic and public health problem. Staphylococcus epidermidis, thanks to its ability to form biofilm and colonize biomaterials, represents the most frequent causative agent involved in biofilm-associated infections of medical devices. Therefore, the research of new molecules able to interfere with S. epidermidis biofilm formation has a remarkable interest. In the present work, the attention was focused on Pseudomonas sp. TAE6080, an Antarctic marine bacterium able to produce and secrete an effective antibiofilm compound. The molecule responsible for this activity was purified by an activity-guided approach and identified by LC-MS/MS. Results indicated the active protein was a periplasmic protein similar to the Pseudomonas aeruginosa PAO1 azurin, named cold-azurin. The cold-azurin was recombinantly produced in E. coli and purified. The recombinant protein was able to impair S. epidermidis attachment to the polystyrene surface and effectively prevent biofilm formation. Full article
Show Figures

Figure 1

Back to TopTop